REGN - NASDAQ

Regeneron Pharmaceuticals, Inc.

REGN·NASDAQ

$618.95

+2.7%

HealthcareBiotechnology

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$63.77B

EPS43.0700

P/E Ratio14.37

Earnings Date07/30/2026

40.56B

Assets

3Y+39.0%

5Y+136.0%

10Y+482.0%

9.30B

Total Liabilities

11%

3Y+42.0%

5Y+52.0%

10Y+269.0%

31.26B

Total Equity

3Y+38.0%

5Y+184.0%

10Y+603.0%

Regeneron Pharmaceuticals, Inc. Funding & Solvency Profile

REGN · NASDAQ

Current Assets

Cash & Cash Equivalents3.12B

Net Receivables5.74B

Inventory3.20B

Other Current Assets474.80M

Total Current Assets18 B

Non-Current Assets

Property, Plant & Equipment5.12B

Goodwill & Intangible Assets1.26B

Long-Term Investments10.26B

Other Non-Current Assets1.82B

Total Non-Current Assets17 B

Total Assets

40.56B

Financial Health Analysis

Current Ratio

4.13x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.30x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

14 B

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

44% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Regeneron Pharmaceuticals, Inc. Balance Sheet

REGN • NASDAQ

Regeneron Pharmaceuticals, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	3.1B	2.5B	2.7B	3.1B	2.9B	2.2B	1.6B	1.5B	812.7M	535.2M	809.1M	648.7M	535.6M	230.3M	483.6M	112.6M	207.1M	247.8M	498.9M	237.9M
Short-Term Investments	5.5B	6.5B	8.1B	4.6B	2.8B	1.4B	1.6B	1.3B	596.8M	503.5M	236.1M	251.8M	158.4M	77.8M	43.3M	136.8M	134.3M	227M	267.5M	221.4M
Cash & Short-Term Investments	8.6B	9B	10.8B	7.7B	5.7B	3.6B	3.2B	2.8B	1.4B	1B	1B	900.5M	694M	308.1M	526.9M	249.4M	341.3M	474.8M	766.5M	459.3M
Net Receivables	5.7B	6.2B	5.7B	5.3B	6B	4.1B	2.8B	2.2B	2B	1.6B	1.5B	976.4M	955M	693.1M	103M	81.9M	65.6M	35.2M	18.3M	7.5M
Accounts Receivables	5.7B	6.2B	5.7B	5.3B	6B	4.1B	2.4B	2.2B	2B	1.6B	1.5B	976.4M	891.8M	693.1M	103M	81.9M	65.6M	35.2M	18.3M	7.5M
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	425M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	3.2B	3.1B	2.6B	2.4B	2B	1.9B	1.4B	1.2B	726.1M	399.4M	238.6M	128.9M	70.4M	28.6M	13.6M	-15.1M	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	411.2M	332.4M	160.8M	273.7M	243.3M	225.1M	130.5M	163.5M	79M	33M	28M	19.2M	24.9M	18.6M	11.5M	13.1M	3.2M
Other Current Assets	474.8M	349.2M	386.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	44.7M	148.1M	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Assets	18B	18.7B	19.5B	15.9B	14B	9.8B	7.7B	8B	5.6B	3.9B	3.4B	2.5B	2.3B	1.6B	913.6M	720.1M	425.5M	521.4M	797.8M	470M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	5.1B	4.6B	4.1B	3.8B	3.5B	3.2B	2.9B	2.6B	2.4B	2.1B	1.6B	974.3M	527M	379.9M	368M	347.5M	259.7M	87.9M	58.3M	49.4M
Intangible Assets	1.3B	1.1B	1B	915.5M	6.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	1.3B	1.1B	1B	915.5M	6.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	10.3B	8.9B	5.4B	6.6B	6.8B	3.1B	3.3B	1.8B	1.5B	864.3M	632.2M	460.2M	389.9M	271.2M	275.9M	370.1M	47.1M	51.1M	0.0	0.0
Tax Assets	4.1B	3.3B	2.6B	1.7B	876.9M	858.9M	824.2M	828.7M	506.3M	825.3M	461.9M	316.1M	231.9M	192M	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	1.8B	1.1B	444.1M	336.4M	216.1M	168.1M	144.7M	127.4M	77.9M	20.3M	5.8M	3M	5.3M	31.3M	14M	14.3M	8.9M	9.7M	1.9M	65.8M
Total Non-Current Assets	22.5B	19.1B	13.6B	13.3B	11.4B	7.4B	7.1B	5.3B	4.4B	3.8B	2.7B	1.8B	1.2B	874.5M	657.8M	731.8M	315.7M	202.8M	138.4M	115.1M
Total Assets	40.6B	37.8B	33.1B	29.2B	25.4B	17.2B	14.8B	11.7B	8.8B	7B	5.6B	3.9B	3B	2.1B	1.3B	1.1B	741.2M	670M	936.3M	585.1M
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.3B	1B	618.3M	589.2M	1.2B	511.1M	418.1M	239M	178.4M	370.8M	141M	99.5M	61.9M	38.9M	27.7M	17.8M	1.2M	16.1M	13M	4.3M
Accounts Payable	939M	789.5M	606.6M	589.2M	564M	475.5M	418.1M	218.2M	178.2M	135M	141M	99.5M	61.9M	38.9M	27.7M	15.6M	18.6M	6.3M	8.1M	4.3M
Other Payables	351.3M	213.2M	11.7M	0.0	613.7M	35.6M	0.0	20.8M	200K	235.8M	0.0	0.0	0.0	0.0	0.0	2.3M	-17.5M	9.8M	4.9M	0.0
Accrued Expenses	2.5B	2.3B	2.3B	2.1B	1.6B	1.6B	1.2B	751.3M	637M	508.3M	503.2M	384M	189M	72.4M	67.9M	23.8M	47.8M	20.1M	26.2M	0.0
Short Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	200M	0.0
Capital Lease Obligations (Current)	0.0	0.0	0.0	0.0	719.7M	0.0	0.0	0.0	0.0	129.6M	0.0	0.0	939K	1.4M	1M	675K	0.0	0.0	0.0	0.0
Tax Payables	0.0	213.2M	0.0	300K	326.3M	19.5M	49.4M	20.8M	227K	235.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	553M	627.7M	458.9M	477.9M	442M	577.7M	591.7M	452.5M	320.1M	231.7M	153.5M	74M	47M	50.8M	300.3M	54.7M	44.5M	209.9M	44.4M	23.5M
Other Current Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	85M	0.0	0.0	1.2M	13.6M	97.1M	0.0	0.0	0.0	12M	0.0	0.0	0.0	0.0
Total Current Liabilities	4.4B	3.9B	3.4B	3.1B	3.9B	2.7B	2.1B	1.4B	1.1B	1.2B	811.2M	654.7M	298.8M	163.6M	148.3M	109.1M	93.6M	83.7M	283.7M	45M
NON-CURRENT LIABILITIES
Long Term Debt	2B	2B	2B	2B	2B	2B	0.0	0.0	0.0	0.0	0.0	146.8M	320.3M	296.5M	275M	0.0	0.0	5.1M	0.0	200M
Deferred Revenue (Non-Current)	208.7M	185.7M	126.7M	69.8M	73.3M	57.8M	105.3M	464.2M	629.2M	830.8M	664.7M	135.2M	184.2M	208.3M	248.6M	285.9M	137.9M	162.4M	192.3M	0.0
Other Non-Current Liabilities	2B	1.6B	854.1M	638M	680.2M	687.1M	395.3M	546.6M	949.3M	100.4M	115.5M	217.1M	11.3M	7.3M	-247.6M	52.6M	4M	0.0	0.0	0.0
Total Non-Current Liabilities	4.9B	4.5B	3.7B	3.4B	2.7B	3.4B	1.6B	1.5B	1.5B	1.3B	1.1B	632.8M	700.1M	671.6M	689.6M	452.6M	250.9M	219M	192.3M	323.5M
Capital Lease Obligations	720M	720M	720M	720M	719.7M	717.2M	713.9M	708.5M	703.5M	481.1M	364.7M	312.3M	185.2M	160.8M	160.5M	160M	109M	0.0	0.0	0.0
Total Liabilities	9.3B	8.4B	7.1B	6.6B	6.7B	6.1B	3.7B	3B	2.6B	2.5B	2B	1.3B	998.9M	835.1M	837.9M	561.6M	344.4M	251.2M	476M	368.5M
SHAREHOLDERS' EQUITY
Treasury Stock	-18.6B	-15.2B	-12.6B	-10.4B	-8.3B	-6.6B	-739.9M	-396.4M	-316.2M	-316.2M	-306.1M	-169.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Common Stock	100K	100K	100K	100K	100K	100K	100K	100K	112K	110K	108K	104K	99K	97K	93K	89K	81K	80K	79K	65K
Additional Paid-In Capital	14B	12.9B	11.4B	9.9B	8.1B	6.7B	4.4B	3.9B	3.5B	3B	3.1B	2.5B	2B	1.8B	1.8B	1.6B	1.3B	1.3B	1.3B	904.4M
Retained Earnings	35.8B	31.7B	27.3B	23.3B	19B	10.9B	7.4B	5.3B	2.9B	1.7B	852.7M	255.4M	-92.7M	-517.1M	-1.3B	-1B	-941.1M	-875.9M	-793.2M	-687.6M
Accumulated Other Comprehensive Income/Loss	77.5M	-7.9M	-80.9M	-238.8M	-26.2M	29.3M	21.1M	-12.3M	640K	-12.8M	8.6M	52.3M	-1.2M	-1.2M	-1.9M	-2.5M	1M	-114K	170K	-231K
Total Stockholders' Equity	31.3B	29.4B	26B	22.7B	18.8B	11B	11.1B	8.8B	6.1B	4.4B	3.7B	2.5B	2B	1.2B	485.7M	527.8M	396.8M	418.9M	460.3M	216.6M
Total Equity	31.3B	29.4B	26B	22.7B	18.8B	11B	11.1B	8.8B	6.1B	4.4B	3.7B	2.5B	2B	1.2B	485.7M	527.8M	396.8M	418.9M	460.3M	216.6M
SUMMARY
Total Liabilities & Equity	40.6B	37.8B	33.1B	29.2B	25.4B	17.2B	14.8B	11.7B	8.8B	7B	5.6B	3.9B	3B	2.1B	1.3B	1.1B	741.2M	670M	936.3M	585.1M
Total Investments	15.7B	15.4B	13.5B	11.2B	9.6B	4.5B	4.9B	3.1B	2.1B	1.4B	868.3M	711.9M	548.3M	349M	319.2M	506.8M	181.3M	278M	345.8M	221.4M
Total Debt	2.7B	2.7B	2.7B	2.7B	2.7B	2.7B	713.9M	708.5M	703.5M	481.1M	375.5M	459.1M	505.5M	457.3M	435.5M	160M	109M	5.1M	202.3M	200M
Net Debt	-412.2M	216.2M	-27.1M	-404.5M	-185.9M	502M	-903.9M	-759.2M	-109.3M	-54.1M	-433.6M	-189.7M	-30.1M	227.1M	-48.1M	47.5M	-98.1M	-242.7M	-296.6M	-37.9M
Shares Outstanding	103,282,318	103,282,318	103,282,318	103,282,318	103,282,318	103,282,318	103,282,318	103,282,318	103,282,318	103,282,318	103,282,318	103,282,318	103,282,318	103,282,318	103,282,318	103,282,318	103,282,318	103,282,318	103,282,318	103,282,318

SEC Filings

REGN - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	April 29, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 29, 2026	April 29, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 24, 2026	June 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 08, 2026	April 08, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 04, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 30, 2026	January 30, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
8-K 8-K 2025 N/A	October 28, 2025	October 28, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	October 28, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 06, 2025	October 06, 2025	2025	View Filing

Showing 1 to 10 of 467 filings

Related Guides

Blog Categories

Continue your REGN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.